I know this is all just fun speculation but I'm stunned by the...

I know this is all just fun speculation but I'm stunned by the lowballing being expressed here, though I acknowledge everyone has a different time horizon that needs to be factored in too.

I think Edwards will take a tilt because they're survival depends on winning it, and they will try to coax every share out of your hands that they possibly can for as little dilution to their existing shareholders as possible. I say tell them to get lost. It's like the other thread on buying AVR shares for $3-$4 ... they had their chance to pick us up cheap, that is long gone now and it's too late. We are pretty much derisked - there might be some delays and bumps on the FDA piece, but the results speak for themselves and I don't think anyone has any real doubts about what the outcome will ultimately be; and then there's executing on commercialisation, but that is already well advanced (the make up of our medical advisory board is one clue, the talk of an upcoming IPO on the NASDAQ in the next 6 months or so is another). We can get to market cost effectively, and will hoover up market share in every direction in only a few years (doctors will move to a game changing new technology very quickly ... think about the liability exposure they take on if they don't). So yes, you can sell to someone like Edwards for $2b, $5b, $10b, $15b .... or you can take the majority of their gigantic market share and a solid chunk of Medtronic's with it.

Put another way, would you sell your $2-3m Sydney home for $200-300k just to get your hands on a cash payout a bit sooner?

I am more interested in a new comer in the TAVR space throwing their hat in the ring ... Boston, Abbott or someone else. They won't be cannibalising their own business so will be able to lob a bid far closer to fair value than the current 2 players.